Navigation Links
Texas Woman Alleges Actos Caused her Bladder Cancer, Parker Waichman LLP Files Lawsuit on Victim’s Behalf
Date:5/6/2013

New York, New York (PRWEB) May 06, 2013

Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a lawsuit on behalf of a Texas woman who developed bladder cancer, allegedly due to using Actos. The suit was filed on April 2, 2013, in the U.S. District Court for the Western District of Louisiana (Case No. 6:13-cv-0704), where it is one of thousands of cases pending in the Actos multidistrict litigation (In Re: Actos (Pioglitazone) Products Liability Litigation, MDL No. 6:11-md-2299). Jerrold S. Parker, founding partner of Parker Waichman LLP, serves on the Plaintiffs’ Steering Committee in the litigation. Takeda Pharmaceuticals, America; Takeda Pharmaceuticals USA, Inc. f/k/a Takeda Pharmaceuticals North America, Inc.; Takeda Pharmaceutical Company Limited; and Eli Lilly and Company have been named as Defendants.

According to the Complaint, the Plaintiff began taking Actos around May 2000 and stopped taking the drug around June 2001, about which time she had developed bladder cancer, allegedly as a result of taking Actos. The Defendants allegedly knew that taking the diabetes drug could lead to an increased risk of bladder cancer, but failed to disclose this information to the Plaintiff, her doctor and other consumers. She is seeking damages for permanent injuries, emotional distress, economic loss due to medical expenses and living-related expenses due to a new lifestyle.

Thousands of Actos lawsuits have been filed in state and federal courts across the country, according to an April 16, 2013, Bloomberg report. Actos is a Type 2 diabetes medication that was approved by the U.S. Food and Drug Administration in 1999. In 2011, the agency updated the label to warn that users may face an increased risk of bladder cancer after taking the drug for only one year

Since then, research has continued to suggest that Actos is associated with bladder cancer. For instance, the May 31, 2012 issue of the British Medical Journal found that Actos users were twice as likely to develop bladder cancer after two years. Then, the July 3, 2012 Canadian Medical Association Journal found that patients taking the medication were 22 percent more likely to get bladder cancer.

Parker Waichman LLP continues to offer free legal consultations to victims of Actos injuries, including bladder cancer, heart problems, and eye injuries. If you or a loved one were diagnosed with bladder cancer after taking Actos, please contact their office by visiting yourlawyer.com. Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).

Contact:
Parker Waichman LLP
Gary Falkowitz, Managing Attorney
(800) LAW-INFO
(800) 529-4636
http://www.yourlawyer.com

Read the full story at http://www.prweb.com/releases/Actos_Texas_mdl/05/prweb10705615.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Texas Veterinary Cancer Registry Expands Nationally
2. North Texas Coaches Announce May 3rd Rick Carson Workshop and Luncheon
3. Skechers Injury Lawsuit Filed on Behalf of a Texas Woman Who Sustained a Number of Serious Injuries Allegedly Due to Design of Skechers Shape-Ups, By Wright & Schulte
4. First Choice Emergency Room Hosts Event in Cypress, Texas to Celebrate the Local Community
5. Dr. Buckingham of Buckingham Center for Facial Plastic Surgery Re-Elected as Texas Medical Association Delegate
6. Texas Truck Accident Lawyers Praise New Safety Technology
7. WINFertility Treatment Program Expands to Central/Southern Texas. Program Makes IVF Treatment More Affordable for Patients Without Infertility Insurance Coverage.
8. North Texas Coaches Announce April 12 Monthly Luncheon Program and Workshop
9. Fresh Healthy Vending Expands to Northern Texas Area to Provide Healthier Options in Vending Machines
10. Ronica N. Holcombe, DPM, of North Texas Foot & Ankle Now Certified to Perform Innovative Surgery for Treatment of Diabetic Neuropathy
11. Texas physician breaks ground in robotic cervical surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... , ... December 09, 2016 , ... "I have gout, ... used this old family recipe, which is meant to relieve gout and pain caused ... me a 12-hour energy boost every time. It relieved what VA doctors called the ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Holy ... in New York, NY, on December 3rd, to benefit Holy Name Medical Center's ... annual event, which raised over $1 million - the largest event in the ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Florida ... Undersea and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. This ... Only a few hospitals and facilities have earned this distinction. This is the ...
(Date:12/8/2016)... ... December 08, 2016 , ... Mirixa Corporation ... adherence, and other pharmacist-delivered patient care services, has announced the promotions of Karen ... to vice president of sales. , Litsinger joined Mirixa in 2008 after ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView Software aims ... employees that are both engaging and easy to use. Coming off the heels ... company revealed today its plans to roll out new AI-powered self-service enhancements to ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec 8, 2016 Research and Markets has announced ... report to their offering. ... This report analyzes the worldwide markets for Endodontic Supplies ... Canada , Japan , Europe ... Rest of World. Annual estimates and forecasts are provided for the ...
(Date:12/8/2016)... Dec. 8, 2016   TriNetX , the ... Children,s Hospital signed a membership agreement to ... development of new cures. The TriNetX ... 57 million patients globally, biopharmaceutical companies and contract ... improve protocol design, site selection, patient recruitment, and ...
(Date:12/8/2016)... 8, 2016  Valeant Pharmaceuticals International, Inc. (NYSE: ... today announced positive results from a Phase 3, ... the safety and efficacy of IDP-118 (halobetasol propionate ... psoriasis. Within the Phase 3 ... severe psoriasis, IDP-118 showed statistical significance to vehicle ...
Breaking Medicine Technology: